The U.S. Food and Drug Administration approved an update to the prescribing information for Kite’s Yescarta® (axicabtagene ciloleucel) on February 6 2026, removing the prior limitation that restricted use to patients with relapsed or refractory primary central nervous system lymphoma (PCNSL). The change allows the CAR‑T therapy to be prescribed to this rare but aggressive patient group.
Gilead’s oncology portfolio gains a new revenue stream as Yescarta’s patient base expands. In the period leading up to February 5 2026, Yescarta generated $1.498 billion in global sales, and the company reported a 5 % increase to $1.6 billion in 2024. While PCNSL represents a small share of the overall market, the approval positions Yescarta to capture a previously untapped niche and strengthens the company’s diversification beyond its dominant HIV franchise.
The CAR‑T market is highly competitive, with Novartis and Bristol Myers Squibb offering alternative therapies. Yescarta’s new PCNSL indication makes it the only CAR‑T product approved for relapsed or refractory large B‑cell lymphoma that can now be used in this specific CNS subset, giving Gilead a unique competitive advantage.
Gilead’s senior leadership has welcomed the approval. Gallia Levy, Senior Vice President and Global Head of Development at Kite, said the decision “expands access for PCNSL patients and reflects the safety profile observed in early studies.” CEO Daniel O’Day noted that the expansion “reinforces our commitment to delivering innovative oncology solutions and broadening the impact of our CAR‑T platform.”
The market reacted positively to the announcement, with analysts highlighting the strong performance of Gilead’s HIV franchise and its liver‑disease segment as key drivers of investor confidence. The PCNSL approval is viewed as a strategic win that complements the company’s broader oncology growth strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.